MedLife S.A. — Earnings Release 2020

Nov 13, 2020

Sediul social: București, Calea Griviței, nr. 365, sector 1, România Codul de înregistrare fiscală: 8422035 Număr de ordine în Registrul Comerţului: J40/3709/1996 Capital social subscris şi vărsat: 5.536.270,5 RON

MedLife Group has focused on helping patients and state institutions during the pandemic and has adapted economically, while providing new medical services requested by patients during this period

• Support to Departments of Public Health by conducting COVID tests and relieving public hospitals by treating chronic patients has been the top priority of MedLife Group throughout this pandemic period • The company has conducted several research studies on the evolution of COVID 19 in Romania, allocating its own resources in this regard

• MedLife will continue to support acute and chronic patients through post-covid recovery projects and the expansion of radiotherapy and oncology services

• The measures to reduce fixed expenses applied by the company in the second quarter have had and will have long-term effects

• The company reported a significant advance in Q3 vs Q2, registering a 47% increase in consolidated Sales, fully recovering sales lost during the period of restrictions on traffic and preventive medical activities

Bucharest, November 13, 2020: Medical System MedLife registered in the first nine months of 2020 consolidated Sales of 770.8 million RON. Compared to the same period last year (9 months 2019) and taking into account the pandemic context and the challenges that arose, consolidated Sales in the period of 9 months 2020 increasead by 8.4 % as compared to the same period last year.

"Despite the pandemic, the flexibility and inventiveness of the management team and the ability to adapt quickly to new services, as well as the mix of medical activities conducted in the areas of hospitals, clinics, corporate, pharma and dentistry, led us to good financial results and we are glad to see that our efforts this year translate into both support for the population and financial performance charts. These results give us an excellent perspective for the period of difficult economic and social recovery after the pandemic and until its end. The proactive attitude and the preventive measures taken in advance, helped us a lot to have control over the situation, to protect our patients and staff and to think about the period to come. The figures look good, we are revving our engines again, we are structuring new business plans, we are reactivating the M&A program and last but not least, we are developing new projects related to tech and research ", said Mihai Marcu, President and CEO of MedLife Group.

The analysis of the financial evolution by quarters, Q2 vs Q3 current year, shows a remarkable recovery at group level, being registered an increase of 47% in Sales. According to MedLife representatives, the laboratories reached the highest increase, of 85%, followed by hospitals, with an increase of 64%, but also by the dentistry line through the Dentestet network, which had a very good return, given the restrictions of operation imposed in the first part of the year.

"As we have shown from the beginning, we have given all the support to the authorities to fight this pandemic, and one of the great actions we have implemented has been the creation in a record time of four COVID-19 laboratories, managing to support the Departments of Public Health in the growing number of tests performed. Moreover, in order to relieve the crowded state hospitals, we have made available the operating theatres and rooms and the medical teams to take care of the chronic patients, closely monitoring

MED LIFE S.A.

Sediul social: București, Calea Griviței, nr. 365, sector 1, România Codul de înregistrare fiscală: 8422035 Număr de ordine în Registrul Comerţului: J40/3709/1996 Capital social subscris şi vărsat: 5.536.270,5 RON

their diseases and giving them the best treatment. We will continue at the same pace", said Mihai Marcu, President and CEO of MedLife Group.

Going forward, for the end of this year, but also for the first months of next year, the company's representatives announced that they will continue to be receptive and proactive to everything this pandemic brings, but at the same time, they will continue post-COVID development and expansion plans.

"Even if the pandemic continues, now our efforts, of all of us, are gaining even more power, with the announcement of the first anti-COVID vaccine. We will continue to be at the forefront, already expressing our readiness to the Ministry of Health to facilitate the distribution of the vaccine and implicitly access to vaccination among the population, to the extent deemed necessary, through our network of over 150 sampling points nationally distributed. In parallel, we want to continue investing, to expand, having at our disposal the new credit increase, amounting to 20 million euros, to which are added important liquidity generated by our business divisions, funds that will be used for the development of several projects on the recovery of patients after COVID-19, and not only. In addition, we are actively pursuing the M&A program and are currently considering the opportunity to join forces with several players, including in the pharma sector, which we believe will make an important contribution to economic recovery and maintaining the health of the population in the years to come. We also turn our attention to projects related to the area of prevention, research and digitalization" said Mihai Marcu, President and CEO of MedLife Group.

"At the same time, we will continue, gradually, the work for the development of MedLife Medical Park project, which has the potential to become in the next period the most complex medical project in Romania in the last 30 years. The new investments and acquisitions will be carefully calibrated according to the evolution of the pandemic", said Mihai Marcu, President and CEO of MedLife Group.